MedTrace Logo

Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

NCT02298985 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-01-15

No results posted yet for this study

Summary

Schizophrenia is still remained one of the disabling disorders despite progress in treatment of mental disturbances. Ten to thirty percents of patients have a little or no benefit from treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of these patients has remained a persistent public health problem since medication-resistant patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from this perennial herb. It possesses a variety of pharmacological activities, including anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic schizophrenia patients.

Conditions

  • Chronic Schizophrenia

Interventions

DRUG

Curcumin

3 g/day (3 capsules/day) for 6 months

DRUG

placebo

3 g/day (3 capsules/day) for 6 months

Sponsors & Collaborators

  • Tirat Carmel Mental Health Center

    collaborator OTHER_GOV

  • Beersheva Mental Health Center

    lead OTHER_GOV

Principal Investigators

  • Vladimir Lerner, MD, PhD · Ben-Gurion University of the Negev

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-01-31
Completion
2017-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02298985 on ClinicalTrials.gov